Therefore, Polish and European guidelines recommend that combination as a preferred first-line treatment in advanced melanoma regardless of BRAF mutation status and especially in patients previously exposed to immunotherapy in the adjuvant setting [2,3,15]. The gene discussed is BRAF; the disease is melanoma.